Niraparib
Brand: Zejula (global) / Niraparib (IN/BD)
Anticancer
PARP inhibitor
Pharmacokinetics
| Half-life | 36 hours |
| Tmax | 3 h |
| Protein Binding | 83 % |
| Volume of Distribution | 1.2 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Preferred in ovarian cancer maintenance. Adjust dose if body weight <77 kg or platelets <150k. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Thrombocytopenia, hypertension, nausea, fatigue
Contraindications:
Uncontrolled hypertension
Precautions:
Monitor BP and CBC regularly